RxDoctor Payments Data

Christopher Rittman, DO

Internal Medicine · Lynn Haven, FLNPI 1235281767

Payments from drug & device makers

$1,104in general payments, 2019–2025

Across 56 payments — averaging $19.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$407
  • Pfizer$125
  • Lilly USA, LLC$106
  • AbbVie$82
  • Merck$57
  • Takeda Pharmaceuticals U.S.A., Inc.$51
  • plus $276 from 10 others

What the payments were for

  • Food & beverage$1,104100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,104 in reported general payments places this provider in the 70th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$40,687
Medicare patients
162
Services billed
1,644

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide11$18,607
RybelsusSemaglutide12$17,311
Ventolin HfaAlbuterol Sulfate11$1,479
Omeprazole60$1,287
Tamsulosin Hcl67$1,027
Metoprolol Succinate32$839
Gabapentin29$740
Losartan Potassium74$730
Pravastatin Sodium33$645
Rosuvastatin Calcium54$543
Levothyroxine Sodium65$488
Atorvastatin Calcium49$484
LevoxylLevothyroxine Sodium11$482
Valsartan15$481
Carvedilol46$421

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$407$35,91823 claims
PfizerLevoxyl$125$48211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Lynn Haven

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →